NCT03980288已完成1 期
A Phase I Clinical Study of 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma
Zhejiang University1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2019年7月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Dose limited toxicity and Maximum Tolerated Dose
研究概览
简要总结
A Phase I Clinical Study of 4th generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma
详细描述
This is a phase I open-label, single and multiple infusion, dose escalation/cohort expansion study to evaluate the safety, cell pharmacokinetics, and preliminary efficacy of CAR-GPC3 T cells, infused intravenously in subjects who have been diagnosed with GPC3 positive advanced hepatocellular carcinoma and refractory or intolerant to current standard systemic treatment.
Primary objectives:
•To evaluate the safety and tolerability of CAR-GPC3 T cells infused intravenously at escalating doses in patients with advanced hepatocellular carcinoma.
Secondary objectives:
- To evaluate the cellular pharmacokinetics of CAR-GPC3 T cells
- To evaluate the overall safety and tolerability of infusion of CAR-GPC3 T cells
- To investigate the preliminary efficacy of CAR-GPC3 T cells in the treatment of advanced hepatocellular carcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 75 years, male or female;
- •Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology who are not suitable for surgery or local treatment, have developed progressive disease or intolerability after standard systemic therapies (including but not limited to systemic chemotherapy, molecular targeted therapy);
- •According to BCLC, the patients are classified into Grade C or Grade B unsuitable for local treatment/progressive disease after local treatment;
- •In tumor tissue samples GPC3 is detected positive by immunohistochemistry (IHC);
- •According to RECIST 1.1, patients have at least one evaluable target lesion, defined as: the longest diameter of non-lymph node lesion ≥ 10 mm, or the shortest diameter of lymph node lesion ≥ 15 mm); hepatic lesions require arterial phase contrast enhancement;
- •Expected survival is > 12 weeks;
- •Cirrhosis status Child-Pugh score:≤7;
- •ECOG Performance Status score: 0 to 1 point;
- •If the patient is HBsAg positive or HBcAb positive, HBV-DNA should be <200 IU/ml. HBsAg positive patients must receive antiviral treatment according to the 2015 China Edition of Guideline for Chronic Hepatitis B Prevention and Treatment;
- •Subjects should have adequate organ functions before screening and pre-treatment (at baseline);
- •Have venous accesses for pheresis;
- •Subjects of childbearing age must undergo a serum pregnancy test within 14 days before the initiation of the study and the result must be negative. In addition, they should be willing to use a reliable method of contraception during the trial (within 52 weeks after cell infusion); male subjects whose spouses are women of childbearing age should undergo sterilization surgery or agree to use a reliable method of contraception during the trial;
- •Understand and sign informed consent.
排除标准
- •Pregnant or breast-feeding women;
- •HCV-RNA, HIV antibodies or Syphilis Serological tests are positive;
- •Any uncontrollable active infection, including but not limited to active tuberculosis;
- •Subjects have clinically significant thyroid dysfunction determined by investigator (serum thyroid hormone assays TT4, TT3, FT3, FT4, and serum thyroid stimulating hormone TSH) which is not suitable for entering into the study;
- •Previous or present hepatic encephalopathy;
- •Current clinically significant ascites, which is defined as ascites that are physically positive or require intervention (e.g., puncture or medication) for control (those whose imaging result shows ascites requiring no intervention may be included);
- •Imaging results:≥50% of the liver is replaced by tumor or portal vein main tumor thrombus, or tumor thrombus invasion of mesenteric vein / inferior vena cava;
- •Patients with known active autoimmune diseases which require to be treated with immunosuppressive agents including biological agents;
- •The side effects caused by the previous treatment of the subjects did not return to CTCAE ≤1; except hair loss and other tolerable events determined by investigator;
- •Patients who had received systemic steroids or other immunosuppressive agents within 2 weeks before collection of mononuclear cells, except those who had recently used or are currently using inhaled steroids;
- •Allergic to immunotherapy and related drugs;
- •Subjects have untreated or symptomatic brain metastases;
- •Subjects have central or extensively metastases in lung;
- •Subjects with unstable or active ulcers and gastrointestinal bleeding currently;
- •Patients with a history of organ transplantation or waiting for organ transplantation (including liver transplantation);
- •Subjects who have undergone antitumor therapy within 2 weeks prior to apheresis;
- •Previously received any chimeric antigen receptor-modified T-cells (CAR-T) , TCR T immunotherapy;
- •Subjects who have undergone PD-1/PD-L1 therapy within 3 months prior to screening;
- •Subjects who have undergone major surgery or significant trauma within 4 weeks prior to apheresis, or who are expected to undergo major surgery during the study;
- •There are no other serious diseases that may limit subjects' participation in this trial;
- •Prior to pretreatment and infusion,the subject has a central nervous system disease sign or an abnormal neurological test result with clinical significance;
- •Prior to pretreatment, subjects developed, including but not limited to, new arrhythmias that could not be controlled with drugs, hypotension requiring pressor agent, bacterial, fungal or viral infections that required intravenous antibiotics. Creatinine clearance rate <50mL/min; The investigator judges that the subject is not suitable for continuing the trial. Subjects who use antibiotics to prevent infection can continue the trials if judged by the investigator;
- •According to the investigators' evaluation, patients are unable or unwilling to comply with the requirements of the study protocol.
研究组 & 干预措施
CAR-GPC3 T Cells
Experimental
The subjects enrolled will be sequentially assigned to Part 1 at 3 dose levels via typical 3+3 dose escalation method and then Part 2, cohort expansion stage, 3 cohorts of CAR T therapy combination with currently available treatment for HCC. stage Part 1: Dose escalating: 3 dose level Part 2: 3 cohorts Cohort 1. Combination with tyrosine kinase inhibitors Cohort 2. Combination with PD-1 / PD-L1 monoclonal antibody Cohort 3. Combination with the drugs may benefit for patient at investigator's discretion
干预措施: CAR-GPC3 T Cells (Drug)
结局指标
主要结局
Dose limited toxicity and Maximum Tolerated Dose
时间窗: After 28 days of single infusion
Safety and tolerability
次要结局
- Antitumor efficacy-Progression-free survival (PFS)(Through study completion, an average of 3 years)
- Antitumor efficacy-Duration of response (DOR)(Through study completion, an average of 3 years)
- Antitumor efficacy-Duration of disease control (DDC)(Through study completion, an average of 3 years)
- Number of participants with treatment-related adverse events(Through study completion, an average of 3 years)
- Antitumor efficacy-Objective response rate (ORR)(Through study completion, an average of 3 years)
- Number of cells(Through week 52 or the second timepoint of cells undetectable)
- Antitumor efficacy-Overall survival (OS)(Through study completion, an average of 3 years)
- Antitumor efficacy-Disease control rate (DCR)(Through study completion, an average of 3 years)
研究者
TingBo Liang
Professor
Zhejiang University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Chimeric Antigen Receptor T Cells Targeting Glypican-3Hepatocellular CarcinomaNCT03884751CARsgen Therapeutics Co., Ltd.9
招募中
1 期
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT06461624Zhejiang University15
终止
不适用
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell MalignanciesB-cell MalignanciesNCT03050190Shenzhen Geno-Immune Medical Institute200
进行中（未招募）
1 期
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)Multiple MyelomaNCT03915184CARsgen Therapeutics Co., Ltd.105
Unknown
1 期
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT03084380Xinqiao Hospital of Chongqing20